Open AccessRelapsed plasmablastic lymphoma in a HIV‐negative patient: Pushing the envelope
Author(s) -
Kathrotiya Manthan,
Radhakrishnan Vivek S,
Bhave Saurabh J,
Kumar Jeevan,
Roychowdhury Mita,
Arun Indu,
Das Jayanta,
Chandy Mammen,
Nair Reena
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3673
Subject(s) - plasmablastic lymphoma , medicine , daratumumab , bortezomib , lymphoma , hematopoietic cell , immunotherapy , salvage therapy , oncology , human immunodeficiency virus (hiv) , melphalan , multiple myeloma , immunology , chemotherapy , haematopoiesis , stem cell , cancer , biology , genetics
This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully and consolidated with an allogeneic haploidentical hematopoietic cell transplantation.